RFA & PFA • Real-Time Lesion Assessment

Closing the recurrence gap in cardiac ablation.

Recurrence is the main unsolved problem in atrial fibrillation ablation. AblaView^®* is a catheter delivering either RFA or PFA energy that provides real-time lesion assessment (contact, stability, lesion size, durability of the ablations, gap detection, pop prediction). The system's ability to detect during ablation whether the procedure will be ineffective was confirmed at 100% specificity for durable PFA at three-month follow-up in the first-in-human study, peer-reviewed in Europace.

*The device presented is under preclinical/clinical investigation. It is not FDA approved nor CE labelled.

Explore the Technology See the Evidence

Why AblaView®

Realtime. Direct. No surrogates.

The lesion durability and gap detection in realtime are the largest unsolved problem in EP ablation procedures. AblaView^® is the only platform that closes it.

For both RF and PF

Contact quality, stability & catheter orientation

Direct optical assessment of contact quality, stability, and catheter orientation at the tip. Real-time identification of gaps during the procedure.

For RF only

Lesion size (diameter and depth) · pop prediction

Optical readout of lesion diameter and depth during RF delivery, plus a validated steam-pop risk model, both measured directly from birefringence at the catheter tip.

For PF only

Durability prediction

100% specificity for durable PFA at three-month follow-up in the first-in-human study (n=10, no hemolysis, no neurovascular complications). Peer-reviewed in Europace, February 2025.

The Enabling Mechanism

PS-OCR: showing what electricity can't.

Polarization-Sensitive Optical Coherence Reflectometry measures tissue birefringence directly, with 50µm axial resolution. Intracardiac ultrasound is around 200µm, so PS-OCR is 4 to 5 times higher resolution. This margin matters because atrial walls are thin, typically 0.6 mm to 1 mm thick, and susceptible to perforation. The physics is what makes the unique performance of AblaView^® possible.

50µm

Axial Resolution

1310 nm swept-source laser resolves individual tissue layers, with 4 to 5× the resolution of intracardiac ultrasound.

50 ms

GUI Refresh Rate

20 frames per second on the clinician’s display, including acquisition and processing by the AblaView^® Clinical AI Engine.

860+

Pre-clinical Ablations with Histology

Animal ablations (GLP and non-GLP) paired with histological ground truth. Good correlation has been observed between the animal and human PS-OCR output.

Co-Authors & Investigators

Peer-reviewed publication record.

Published in Europace, 2025. Preclinical PS-OCR validation in Circulation, 2024.

Co-author on the AblaView® first-in-human Europace publication, February 2025. Proctor during the first-in-human cases.

Prof. Atul Verma, MD

Director of Cardiology, McGill University Health Centre. 300+ peer-reviewed publications including NEJM. Led STAR AF II.

Co-author on the AblaView® first-in-human Europace publication, February 2025. Proctor during the first-in-human cases.

Prof. Raphaël Martins, MD, PhD

Cardiac Electrophysiologist, CHU Rennes / University of Rennes. AF mechanisms and translational ablation research.

Lead author on the AblaView® PS-OCR preclinical study published in Circulation, 2024. Directs the Preclinical Cardiovascular Lab at Sunnybrook. Specialist in preclinical evaluation of novel ablation devices.

Dr. Maria Terricabras, MD

Cardiac EP and Director, Preclinical Cardiovascular Lab, Sunnybrook / University of Toronto.

See the evidence. Explore the system.

Dive deeper into the science and the data behind AblaView®.

See the Technology View Clinical Data